House floor advances insurer coverage requirement for scalp-cooling during chemotherapy
Loading...
Summary
Delegates advanced a committee-backed bill directing insurers to cover scalp-cooling systems for chemotherapy patients after floor members questioned scope and fiscal impacts; sponsor cited a Maryland Health Care Commission 2025 cost analysis and committee vote (reported 17–2).
A bill requiring health insurers to cover scalp-cooling systems for patients undergoing tumor-related chemotherapy moved forward on the Maryland House floor after floor questioning on Tuesday.
The bill’s floor representative described the technology as a treatment “provided to a chemotherapy patient, primarily, tumor related chemotherapy, breast cancer,” that cools the scalp during treatment to reduce hair loss, saying it can ease a traumatic side effect for patients and families. The sponsor noted a Maryland Health Care Commission cost analysis from 2025 and said the committee’s fiscal review showed “some overall cost savings in terms of using this.”
A delegate asked whether the measure amounted to Medicaid expansion and pressed who would be directed to act. The sponsor responded that it is not Medicaid expansion and that the bill directs insurance carriers to cover scalp-cooling, adding that committee consideration was not unanimous and that the committee vote was reported as 17–2 in committee. After floor discussion, the House ordered the bill printed for third reading.
Why it matters: Supporters framed the proposal as reducing a highly visible and psychologically harmful chemotherapy side effect; opponents sought clarity on cost, scope and who would bear the expense. The House’s next procedural step is third reading, where lawmakers may again debate details or offer amendments.
What’s next: The bill was ordered printed for third reading; no final passage vote was recorded on the floor during this session.

